NASDAQ:SRPT
Sarepta Therapeutics Stock News
$130.83
-0.550 (-0.419%)
At Close: May 20, 2024
Sarepta Falls 50% To 10-Month Low After DMD Gene Therapy Study Misses Primary Endpoint
08:50am, Friday, 08'th Jan 2021
Shares of Sarepta Therapeutics Inc (NASDAQ: SRPT), which had a lot riding on its gene therapy candidate for treating Duchenne muscular dystrophy in the new year, are sinking. What Happened: Cambridge,
Sarepta Therapeutics to Present at the 39th Annual J.P. Morgan Healthcare Conference
08:30am, Friday, 08'th Jan 2021
CAMBRIDGE, Mass., Jan. 08, 2021 (GLOBE NEWSWIRE) -- Sarepta Therapeutics, Inc. (NASDAQ:SRPT), the leader in precision genetic medicine for rare diseases, today announced that senior management will pr
Sarepta stock plunges more than 50% after mixed results from drug study
05:13pm, Thursday, 07'th Jan 2021
Sarepta Therapeutics Inc. shares lost more than half their value in after-hours trading Thursday, after the company said a drug candidate produced mixed results in a clinical study.
-- Study met the primary biological endpoint of micro-dystrophin protein expression at 12 weeks post-treatment, as measured by western blot, in SRP-9001-treated participants versus placebo -- -- SRP-9
Sarepta Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
06:30pm, Thursday, 31'st Dec 2020
CAMBRIDGE, Mass., Dec. 31, 2020 (GLOBE NEWSWIRE) -- Sarepta Therapeutics, Inc. (NASDAQ:SRPT), the leader in precision genetic medicine for rare diseases, granted equity awards on December 31, 2020 tha
Sarepta, Amicus Top Biotech Picks Ahead Of Key Binary Events: Analyst
02:00pm, Friday, 18'th Dec 2020
Biopharma stocks are risky investment bets that sway wildly in reaction to catalytic events. Binary events scheduled for Amicus Therapeutics, Inc. (NASDAQ: FOLD) and Sarepta Therapeutics Inc (NASDAQ:
Personalis Announces the Launch of SHERPA™ for High-Accuracy Neoantigen Prediction and Cancer Diagnostic Biomarker Development
09:07am, Thursday, 17'th Dec 2020
MENLO PARK, Calif.--(BUSINESS WIRE)---- $SRPT #PrecisionOncology--Personalis Announces the Launch of SHERPA™ for High-Accuracy Neoantigen Prediction and Cancer Diagnostic Biomarker Development
Sarepta Therapeutics Announces Executive Management Changes
08:30am, Monday, 14'th Dec 2020
-- Ian Estepan named chief financial officer -- Dallan Murray named chief commercial officer -- Louise Rodino-Klapac, Ph.D., named chief scientific officer -- Ty Howton, general counsel, to retire fro
Sarepta Therapeutics, Inc. (SRPT) CEO Doug Ingram on MOMENTUM Multiple-Ascending Dose Study of SRP-5051 for Duchenne Muscular Dystrophy Conference (Transcript)
-- Results from the multiple - ascending dose trial demonstrate proof-of-concept for SRP-5051 and support continued dose escalation -- -- At a total dose exposure approximately 10x lower than eteplirs
CAMBRIDGE, Mass., Dec. 04, 2020 (GLOBE NEWSWIRE) -- Sarepta Therapeutics, Inc. (NASDAQ:SRPT), the leader in precision genetic medicine for rare diseases, today announced that on Monday, Dec. 7, 2020 a
Sarepta Therapeutics, Inc. (SRPT) Presents at Evercore ISI HealthCONx Conference - (Transcript)
06:01pm, Wednesday, 02'nd Dec 2020
Sarepta Therapeutics, Inc. (SRPT) Presents at Evercore ISI HealthCONx Conference - (Transcript)
Sarepta Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
06:05pm, Monday, 30'th Nov 2020
CAMBRIDGE, Mass., Nov. 30, 2020 (GLOBE NEWSWIRE) -- Sarepta Therapeutics, Inc. (NASDAQ:SRPT), the leader in precision genetic medicine for rare diseases, granted equity awards on November 30, 2020 tha
Sarepta Therapeutics to Present at the Evercore ISI 3rd Annual HealthCONx Virtual Conference
08:30am, Wednesday, 25'th Nov 2020
CAMBRIDGE, Mass., Nov. 25, 2020 (GLOBE NEWSWIRE) -- Sarepta Therapeutics, Inc. (NASDAQ:SRPT), the leader in precision genetic medicine for rare diseases, today announced that senior management will pa
Sarepta Therapeutics Named One of The Boston Globe's Top Places to Work 2020
08:30am, Friday, 20'th Nov 2020
-- Sarepta is h onored to be recognized for offering a range of benefits and work-life resources to employees and supporting the local community -- -- Rankings based on confidential survey information